International Federation of Pharmaceutical Manufacturers & Associations provided expert commentary on non-communicable diseases, mental and neurological disorders, R&D for diseases of the developing world, counterfeit medicines, vaccines, and neglected tropical diseases Geneva, 28 May 2013, As a nongovernmental organization (NGO) in official relations with the World Health Organization (WHO), the International Federation of Pharmaceutical Manufacturers...
Read moreIFPMA Statement under WHA 66 agenda item 13.2 on Draft action plan for the prevention and control of noncommunicable diseases 2013–2020 Delivered by Mr Mario Ottiglio, Director, Public Affairs and Global Health Policy Thank you on behalf of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), for the opportunity to provide our perspective on...
Read moreIFPMA Statement, WHA 66, Item 16.2, Neglected tropical diseases Delivered by Mr Mario Ottiglio, Director, Public Affairs and Global Health Policy Thank you for the opportunity to contribute to this important discussion today. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry associations across the world IFPMA highly commends the WHO...
Read moreIFPMA statement under WHA 66 agenda item 16.1 on Global Vaccine Action Plan (GVAP) Delivered by Laetitia Bigger, Senior Manager, Vaccines Policy 25 May 2013 Thank you for the opportunity to contribute to this important discussion. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry associations across the world. Mr. Chairman,...
Read moreIFPMA Statement, WHA 66, Item 17.2, Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination Delivered by Mr Mario Ottiglio, Director, Public Affairs and Global Health Policy Thank you on behalf of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) for the opportunity to provide our...
Read moreIFPMA Statement under WHA 66 agenda item 17.1 on Substandard / spurious / falsely-labelled / falsified / counterfeit medical products Delivered by Mr Mario Ottiglio, Director, Public Affairs and Global Health Policy Thank you on behalf of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), for the opportunity to provide our perspective on this...
Read moreIFPMA Statement, WHA 66, Item 13.3, Mental Health Delivered by Mr Mario Ottiglio, Director, Public Affairs and Global Health Policy Thank you for the opportunity to contribute to this leading discussion today. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry associations worldwide. IFPMA highly commends the WHO Secretariat for its...
Read moreCampaign launched during World Health Assembly, where world’s health ministers gather to address the large physical and economic costs of these disorders Mental and neurological disorders (MNDs) affect 700 million people annually and account for 30 percent of global non-communicable disease (NCD) burden ‘Do You Mind?’ helps patients, family members, policymakers and others to understand...
Read moreUNODC Commission on Crime Prevention and Criminal Justice, 22nd session IFPMA statement under item 7 of the provisional agenda on World crime trends and emerging issues and responses in the field of crime prevention and criminal justice Countering fraudulent medicines, in particular their trafficking Delivered by Cyntia Genolet, Policy Analyst, Public Affairs and Global Health...
Read morePeer-reviewed article in Vaccine addresses the 4As of vaccine access – availability, affordability, adoption and alliances Paper’s recommendations offer insights on how to achieve the Decade of Vaccine’s goal of 90% global vaccine coverage by 2020. Increased vaccine awareness, predictable demand, and sustainable financing among 26 expert recommendations to support vaccine access and innovation A...
Read morePartnership is a novel cross-sector collaboration, responding to the United Nations call to tackle non-communicable diseases (NCDs) Initiative goes beyond awareness-raising campaigns by prompting behavioral changes Strategically combining expertise from pharmaceutical and humanitarian sectors, this initiative is expected to reach three million people The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and the...
Read moreBiopharmaceutical incremental innovation increases therapeutic benefits and the number of treatment options available to healthcare providers and patients To better address patients’ needs, researchers constantly seek to reduce dosing frequency, improve tolerability of existing medicines, and minimize the potential for drug-drug interactions The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) today launches a new...
Read more